Analysts Set Immunome, Inc. (NASDAQ:IMNM) Price Target at $33.45

Shares of Immunome, Inc. (NASDAQ:IMNM) have received an average rating of “Moderate Buy” from the twelve ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, ten have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $32.8182.

Several research firms have issued reports on IMNM. Wall Street Zen raised shares of Immunome from a “sell” rating to a “hold” rating in a report on Saturday. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Immunome in a report on Wednesday. Craig Hallum increased their price objective on shares of Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Stephens decreased their price objective on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. Finally, Leerink Partners decreased their price objective on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a report on Friday.

Insider Buying and Selling at Immunome

In other Immunome news, CFO Max Rosett sold 65,000 shares of the stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $21.92, for a total transaction of $1,424,800.00. Following the transaction, the chief financial officer directly owned 54,037 shares of the company’s stock, valued at $1,184,491.04. This trade represents a 54.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Philip Wagenheim sold 36,800 shares of the stock in a transaction on Friday, March 20th. The shares were sold at an average price of $20.47, for a total transaction of $753,296.00. Following the transaction, the director directly owned 369,347 shares in the company, valued at approximately $7,560,533.09. The trade was a 9.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 139,438 shares of company stock valued at $2,964,664 over the last ninety days. Corporate insiders own 7.21% of the company’s stock.

Hedge Funds Weigh In On Immunome

Several hedge funds and other institutional investors have recently modified their holdings of IMNM. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Immunome by 44.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,821 shares of the company’s stock worth $316,000 after buying an additional 14,398 shares in the last quarter. Creative Planning acquired a new stake in Immunome during the second quarter worth about $167,000. Rhumbline Advisers increased its position in Immunome by 22.0% during the second quarter. Rhumbline Advisers now owns 108,414 shares of the company’s stock worth $1,008,000 after purchasing an additional 19,526 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Immunome by 3.6% during the second quarter. The Manufacturers Life Insurance Company now owns 280,816 shares of the company’s stock worth $2,612,000 after purchasing an additional 9,686 shares during the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Immunome during the second quarter valued at about $1,021,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

Immunome Stock Performance

Shares of NASDAQ IMNM opened at $20.88 on Friday. The company’s fifty day moving average price is $21.96 and its 200 day moving average price is $21.19. Immunome has a 1 year low of $7.74 and a 1 year high of $27.65. The company has a market capitalization of $2.36 billion, a PE ratio of -8.77 and a beta of 2.11.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. On average, equities analysts expect that Immunome will post -2.26 EPS for the current year.

Immunome News Summary

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Immunome and kept a $40 price target, signaling meaningful upside expectations. Immunome (NASDAQ:IMNM) Given “Buy” Rating at HC Wainwright
• Positive Sentiment: Both HC Wainwright and Lifesci Capital raised earnings estimates for multiple 2026 and 2027 periods, suggesting improved operating expectations. Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), Coherus Biosciences (CHRS)
• Neutral Sentiment: Analyst forecasts still show Immunome posting losses in 2026 and 2027, keeping attention on future clinical and commercial execution rather than near-term earnings.
• Neutral Sentiment: Lifesci Capital’s Q4 2026 estimate was still slightly negative despite being updated, reflecting cautious expectations for profitability.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.